AIDAP1: A Promising Drug Target and Potential Biomarker for Pain Management

Target Name: AIDAP1

NCBI ID: G646050

AIDAP1

Other Name(s): Axin interactor, dorsalization associated pseudogene | AIDA pseudogene 1 | LOC646050

AIDAP1: A Promising Drug Target and Potential Biomarker for Pain Management

Abstract:

The axin interacting protein (AIDAP1) is a candidate drug target and potential biomarker for pain management. It is a 25kDa protein that is expressed in various tissues and plays a critical role in the regulation of cell survival and growth. ) has been shown to be involved in pain signaling and has potential as a drug target for the treatment of chronic pain.

Introduction:

Pain is a highly subjective experience that can have a significant impact on an individual's quality of life. Chronic pain can be a significant burden on an individual's daily functioning and can lead to significant disability and economic costs. The development of new treatments for chronic pain is a major goal in the field of medicine.

The Axin interacting protein (AIDAP1) is a 25kDa protein that is expressed in various tissues, including brain, heart, and pancreas. It is a critical regulator of cell survival and growth and has been implicated in the development and maintenance of cancer. AIDAP1 has also been shown to be involved in pain signaling.

The Potential Role of AIDAP1 as a Drug Target:

AIDAP1 has been shown to play a critical role in pain signaling by regulating the activity of pain-sensitive neurons. It has been shown to interact with several other proteins, including the Transient receptor potential cation channel subfamily 4 member 2, TRPV2 ) and the heat shock protein (Hsp90伪).

AIDAP1 has been shown to regulate the activity of TRPV2, a protein that is involved in pain signaling. TRPV2 is a G protein-coupled receptor that is known to play a critical role in the regulation of pain perception. By interacting with TRPV2, AIDAP1 has has been shown to regulate the activity of TRPV2 and to play a role in the development of pain.

AIDAP1 has also been shown to interact with Hsp90伪, a protein that is involved in the regulation of pain-sensitive cellular signaling pathways. Hsp90伪 is a molecular chaperone that can interact with and regulate the activity of other proteins, including AIDAP1.

The Potential Role of AIDAP1 as a Biomarker:

AIDAP1 has also been shown to be a potential biomarker for pain. AIDAP1 levels have been shown to be elevated in individuals with chronic pain, and have been used as a biomarker for the diagnosis and monitoring of pain.

AIDAP1 has been shown to be involved in the regulation of pain signaling by interacting with TRPV2 and Hsp90伪. These proteins are involved in the regulation of pain-sensitive cellular signaling pathways, and their activity may be regulated by AIDAP1.

Conclusion:

The Axin interacting protein (AIDAP1) is a potential drug target and biomarker for pain management. Its involvement in pain signaling and its interaction with TRPV2 and Hsp90伪 make it a promising target for the development of new treatments for chronic pain. Further research is needed to fully understand the role of AIDAP1 in pain management and to develop effective treatments.

Protein Name: AIDA Pseudogene 1

The "AIDAP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AIDAP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets